Merck & Co Inc (MRK)
99.85
+2.41
(+2.47%)
USD |
NYSE |
Nov 21, 16:00
99.94
+0.09
(+0.09%)
After-Hours: 20:00
Merck Enterprise Value: 270.08B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 270.08B |
| November 19, 2024 | 267.81B |
| November 18, 2024 | 267.86B |
| November 15, 2024 | 267.23B |
| November 14, 2024 | 272.41B |
| November 13, 2024 | 272.77B |
| November 12, 2024 | 272.97B |
| November 11, 2024 | 278.41B |
| November 08, 2024 | 283.95B |
| November 07, 2024 | 279.52B |
| November 06, 2024 | 278.41B |
| November 05, 2024 | 280.73B |
| November 04, 2024 | 281.29B |
| November 01, 2024 | 281.32B |
| October 31, 2024 | 282.43B |
| October 30, 2024 | 289.03B |
| October 29, 2024 | 286.24B |
| October 28, 2024 | 287.51B |
| October 25, 2024 | 286.88B |
| October 24, 2024 | 291.69B |
| October 23, 2024 | 292.95B |
| October 22, 2024 | 293.61B |
| October 21, 2024 | 292.85B |
| October 18, 2024 | 298.83B |
| October 17, 2024 | 301.49B |
| Date | Value |
|---|---|
| October 16, 2024 | 303.18B |
| October 15, 2024 | 305.99B |
| October 14, 2024 | 301.33B |
| October 11, 2024 | 301.44B |
| October 10, 2024 | 300.60B |
| October 09, 2024 | 302.80B |
| October 08, 2024 | 298.37B |
| October 07, 2024 | 298.55B |
| October 04, 2024 | 301.54B |
| October 03, 2024 | 302.58B |
| October 02, 2024 | 307.39B |
| October 01, 2024 | 314.12B |
| September 30, 2024 | 311.13B |
| September 27, 2024 | 314.68B |
| September 26, 2024 | 313.16B |
| September 25, 2024 | 317.32B |
| September 24, 2024 | 317.90B |
| September 23, 2024 | 319.60B |
| September 20, 2024 | 323.50B |
| September 19, 2024 | 323.66B |
| September 18, 2024 | 327.23B |
| September 17, 2024 | 326.34B |
| September 16, 2024 | 325.51B |
| September 13, 2024 | 320.18B |
| September 12, 2024 | 318.64B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
176.33B
Minimum
Mar 23 2020
365.42B
Maximum
Jun 24 2024
259.61B
Average
241.79B
Median
Enterprise Value Benchmarks
| Amgen Inc | 206.13B |
| Johnson & Johnson | 384.09B |
| Eli Lilly and Co | 742.91B |
| Pfizer Inc | 198.27B |
| Moderna Inc | 7.348B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.157B |
| Revenue (Quarterly) | 16.66B |
| Total Expenses (Quarterly) | 12.67B |
| EPS Diluted (Quarterly) | 1.24 |
| Gross Profit Margin (Quarterly) | 75.51% |
| Profit Margin (Quarterly) | 18.95% |
| Earnings Yield | 4.78% |
| Operating Earnings Yield | 5.58% |
| Normalized Earnings Yield | 4.940 |